So What Happens if Medicare Stops Paying Its Bills?

The “elephant in the room” is the shifting, uncertain complexity of our regulatory and legislative environment. Exactly to that point, on Wednesday, March 27th Dr. Scott Gottlieb, a Forbes contributor focusing on policy, regulation, and public health posted an article entitled “Medicare Has Stopped Paying Bills For Medical Diagnostic Tests. Patients Will Feel”, which instantly caused a collective shiver among some diagnostics-focused investors and advisory groups. Experts shared their views on the Forbes article and its implications with us.

Read more »

Meaningful Use, The Affordable Care Act, Sequestration, and Medical Devices

The Healthcare ecosystem in the United States is changing dramatically due to significant regulations and legislation. Though Obamacare gets the most attention for its impact on patient care and healthcare coverage, legislation such as the Meaningful Use Regulations passed in 2009, followed by the passage of the Affordable Care Act in 2010, and the most recent Sequestration may have a profound impact on the opportunities for developing medical devices and medical device investors.

Read more »

2013, A Year for Point-of-Care Diagnostics Growth

Response Biomedical Corp. (RBM.TO)(RPBIF) is bringing in 2013 with a bang announcing their 2nd US distribution deal since the 1st week in January. Earlier in the month Response Biomedical entered a distribution agreement with US hospital supplier Laboratory Supply Company Inc. (Labsco) to distribute its cardiovascular portfolio of RAMP® products to small hospitals. By the end of January Response Biomedical announced their 2nd US distribution agreement with Fishers Healthcare for their RAMP® Flu A + B tests and RAMP® RSV test on the RAMP® 200.

Read more »

Clinical Trials Managed in “The Cloud?”

The fundamental concept of cloud computing dates back to the 1960s, when John McCarthy was quoted as saying “computation may someday be organized as public utility.”

Read more »